Peng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peng Zhang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Hang Fan
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology
2 shared publications - Huaiwu He
Department of Critical Care Medicine, Peking Union Medical College Hospital , Beijing 100730 , China
2 shared publications - Jinman Li
State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology , Beijing 100071 , China
2 shared publications - Kang Ning
Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular-Imaging, Center of AI Biology, Department of Bioinformatics and Systems Biology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China
2 shared publications - Longxiang Su
Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 shared publications - Maozhen Han
School of Life Sciences, Anhui Medical University
2 shared publications
Latest Publications
- Open Access
- 10 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Large Multicohort Study Reveals a Prostate Cancer Susceptibility Allele at 5p15 Regulating TERT via Androgen Signaling-Orchestrated Chromatin Binding of E2F1 and MYC
Aberrant telomerase reverse transcriptase (TERT) expression is crucial for tumor survival and cancer cells escaping apoptosis. Multiple TERT-locus variants at 5p15 have been discovered in association with cancer risk, yet the underlying mechanisms and clinical impacts remain unclear. Here, our association studies showed that the TERT promoter variant rs2853669 confers a risk of prostate cancer (PCa) in different ethnic groups. Further functional investigation revealed that the allele-specific binding of MYC and E2F1 at TERT promoter variant rs2853669 associates with elevated level of TERT in PCa. Mechanistically, androgen stimulations promoted the binding of MYC to allele T of rs2853669, thereby activating TERT, whereas hormone deprivations enhanced E2F1 binding at allele C of rs2853669, thus upregulating TERT expression. Notably, E2F1 could cooperate with AR signaling to regulate MYC expression. Clinical data demonstrated synergistic effects of MYC/E2F1/TERT expression or with the TT and CC genotype of rs2853669 on PCa prognosis and severity. Strikingly, single-nucleotide editing assays showed that the CC genotype of rs2853669 obviously promotes epithelial–mesenchymal transition (EMT) and the development of castration-resistant PCa (CRPC), confirmed by unbiased global transcriptome profiling. Our findings thus provided compelling evidence for understanding the roles of noncoding variations coordinated with androgen signaling and oncogenic transcription factors in mis-regulating TERT expression and driving PCa.
- 10 November 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Open AccessLarge Multicohort Study Reveals a Prostate Cancer Susceptibility Allele at 5p15 Regulating TERT via Androgen Signaling-Orchestrated Chromatin Binding of E2F1 and MYC
Aberrant telomerase reverse transcriptase (TERT) expression is crucial for tumor survival and cancer cells escaping apoptosis. Multiple TERT-locus variants at 5p15 have been discovered in association with cancer risk, yet the underlying mechanisms and clinical impacts remain unclear. Here, our association studies showed that the TERT promoter variant rs2853669 confers a risk of prostate cancer (PCa) in different ethnic groups. Further functional investigation revealed that the allele-specific binding of MYC and E2F1 at TERT promoter variant rs2853669 associates with elevated level of TERT in PCa. Mechanistically, androgen stimulations promoted the binding of MYC to allele T of rs2853669, thereby activating TERT, whereas hormone deprivations enhanced E2F1 binding at allele C of rs2853669, thus upregulating TERT expression. Notably, E2F1 could cooperate with AR signaling to regulate MYC expression. Clinical data demonstrated synergistic effects of MYC/E2F1/TERT expression or with the TT and CC genotype of rs2853669 on PCa prognosis and severity. Strikingly, single-nucleotide editing assays showed that the CC genotype of rs2853669 obviously promotes epithelial–mesenchymal transition (EMT) and the development of castration-resistant PCa (CRPC), confirmed by unbiased global transcriptome profiling. Our findings thus provided compelling evidence for understanding the roles of noncoding variations coordinated with androgen signaling and oncogenic transcription factors in mis-regulating TERT expression and driving PCa.
- Open Access
- 17 February 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 18 (6) , 696-707
Classification of the Gut Microbiota of Patients in Intensive Care Units During Development of Sepsis and Septic Shock
The gut microbiota of intensive care unit (ICU) patients displays extreme dysbiosis associated with increased susceptibility to organ failure, sepsis, and septic shock. However, such dysbiosis is difficult to characterize owing to the high dimensional complexity of the gut microbiota. We tested whether the concept of enterotype can be applied to the gut microbiota of ICU patients to describe the dysbiosis. We collected 131 fecal samples from 64 ICU patients diagnosed with sepsis or septic shock and performed 16S rRNA gene sequencing to dissect their gut microbiota compositions. During the development of sepsis or septic shock and during various medical treatments, the ICU patients always exhibited two dysbiotic microbiota patterns, or ICU-enterotypes, which could not be explained by host properties such as age, sex, and body mass index, or external stressors such as infection site and antibiotic use. ICU-enterotype I (ICU E1) comprised predominantly Bacteroides and an unclassified genus of Enterobacteriaceae, while ICU-enterotype II (ICU E2) comprised predominantly Enterococcus. Among more critically ill patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores > 18, septic shock was more likely to occur with ICU E1 (P = 0.041). Additionally, ICU E1 was correlated with high serum lactate levels (P = 0.007). Therefore, different patterns of dysbiosis were correlated with different clinical outcomes, suggesting that ICU-enterotypes should be diagnosed as independent clinical indices. Thus, the microbial-based human index classifier we propose is precise and effective for timely monitoring of ICU-enterotypes of individual patients. This work is a first step toward precision medicine for septic patients based on their gut microbiota profiles.
- 17 February 2021
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 18 (6) , 696-707
Open AccessClassification of the Gut Microbiota of Patients in Intensive Care Units During Development of Sepsis and Septic Shock
The gut microbiota of intensive care unit (ICU) patients displays extreme dysbiosis associated with increased susceptibility to organ failure, sepsis, and septic shock. However, such dysbiosis is difficult to characterize owing to the high dimensional complexity of the gut microbiota. We tested whether the concept of enterotype can be applied to the gut microbiota of ICU patients to describe the dysbiosis. We collected 131 fecal samples from 64 ICU patients diagnosed with sepsis or septic shock and performed 16S rRNA gene sequencing to dissect their gut microbiota compositions. During the development of sepsis or septic shock and during various medical treatments, the ICU patients always exhibited two dysbiotic microbiota patterns, or ICU-enterotypes, which could not be explained by host properties such as age, sex, and body mass index, or external stressors such as infection site and antibiotic use. ICU-enterotype I (ICU E1) comprised predominantly Bacteroides and an unclassified genus of Enterobacteriaceae, while ICU-enterotype II (ICU E2) comprised predominantly Enterococcus. Among more critically ill patients with Acute Physiology and Chronic Health Evaluation II (APACHE II) scores > 18, septic shock was more likely to occur with ICU E1 (P = 0.041). Additionally, ICU E1 was correlated with high serum lactate levels (P = 0.007). Therefore, different patterns of dysbiosis were correlated with different clinical outcomes, suggesting that ICU-enterotypes should be diagnosed as independent clinical indices. Thus, the microbial-based human index classifier we propose is precise and effective for timely monitoring of ICU-enterotypes of individual patients. This work is a first step toward precision medicine for septic patients based on their gut microbiota profiles.
- Open Access
Accurate Classification of the Gut Microbiota of Patients in Intensive Care Units During the Development of Sepsis and Septic Shock
The gut microbiota of intensive care unit (ICU) patients display extreme dysbiosis, which is associated with increased susceptibility to organ failure, sepsis and septic shock. However, this dysbiosis is hard to be characterized for each patient, owing to the highly dimensional complexity of gut microbiota. We thus tested whether the concept of enterotype can be applied to the gut microbiota of ICU patients, to describe the dysbiosis. We collected 131 fecal samples from a cohort of 64 ICU patients diagnosed with sepsis or septic shock, using 16S rRNA gene sequencing to dissect their gut microbiota compositions. We find that during the development of sepsis or septic shock, as well as various medical treatments, ICU patients always contain two patterns of dysbiotic microbiota named as ICU-enterotypes, which cannot be explained by the individual host properties such as age, gender and body mass index, as well as external stressors such as infection sites and antibiotic use. ICU-enterotype I comprised predominantly Bacteroides and an unclassified genus of family Enterobacteriaceae , while ICU-enterotype II comprised predominantly Enterococcus . Among more critically ill patients with acute physiology and chronic health evaluation (APACHE) II score > 18, samples of septic shock were more likely to present with ICU-enterotype I ( p = 0.041). Additionally, ICU-enterotype I was correlated with high serum lactate level ( p = 0.007). Therefore, different patterns of dysbiosis are correlated with different clinical outcomes, suggesting that the diagnosis of ICU-enterotypes as an independent clinical index is crucial. For this purpose, the microbial-based human index (MHI) classifier we proposed shows high precision and effectiveness in timely monitoring of ICU-enterotypes of an individual patient. Together, our work serves as the first step toward precision medicine for septic patients based on the gut microbiota profile.
Open AccessAccurate Classification of the Gut Microbiota of Patients in Intensive Care Units During the Development of Sepsis and Septic Shock
The gut microbiota of intensive care unit (ICU) patients display extreme dysbiosis, which is associated with increased susceptibility to organ failure, sepsis and septic shock. However, this dysbiosis is hard to be characterized for each patient, owing to the highly dimensional complexity of gut microbiota. We thus tested whether the concept of enterotype can be applied to the gut microbiota of ICU patients, to describe the dysbiosis. We collected 131 fecal samples from a cohort of 64 ICU patients diagnosed with sepsis or septic shock, using 16S rRNA gene sequencing to dissect their gut microbiota compositions. We find that during the development of sepsis or septic shock, as well as various medical treatments, ICU patients always contain two patterns of dysbiotic microbiota named as ICU-enterotypes, which cannot be explained by the individual host properties such as age, gender and body mass index, as well as external stressors such as infection sites and antibiotic use. ICU-enterotype I comprised predominantly Bacteroides and an unclassified genus of family Enterobacteriaceae , while ICU-enterotype II comprised predominantly Enterococcus . Among more critically ill patients with acute physiology and chronic health evaluation (APACHE) II score > 18, samples of septic shock were more likely to present with ICU-enterotype I ( p = 0.041). Additionally, ICU-enterotype I was correlated with high serum lactate level ( p = 0.007). Therefore, different patterns of dysbiosis are correlated with different clinical outcomes, suggesting that the diagnosis of ICU-enterotypes as an independent clinical index is crucial. For this purpose, the microbial-based human index (MHI) classifier we proposed shows high precision and effectiveness in timely monitoring of ICU-enterotypes of an individual patient. Together, our work serves as the first step toward precision medicine for septic patients based on the gut microbiota profile.
- Open Access
- 7 July 2017
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 18 (9) , 660-665
Clinicopathological characteristics and experience in the treatment of giant retroperitoneal liposarcoma: A case report and review of the literature
Retroperitoneal liposarcoma (RPLS) is a rare tumor, especailly those over 20 kg that are called “giant liposarcoma," whose characteristics and treatments remain relatively unknown. Herein, we report a giant RPLS measuring 65 × 45 × 30 cm in diameter and 31 kg in weight, which we successfully performed complete excision through interdisciplinary cooperation. The patient had an uneventful postoperative course and was discharged without complications. Afterwards he underwent radiotherapy and had no evidence of tumor recurrence or symptoms of metastasis at 3-month CT scan and 8-month follow-up. We also first review the 13 cases reported in literature published in PubMed regarding giant RPLS. Giant RPLS commonly occurs in adults aged 40–60 y and presents atypical clinical manifestations. CT scan is the most useful examination and preoperative biopsy is controversial. Complete surgical resection still remains the principal treatment. Giant RPLS can also be removed, even reach to R0 excision, by a multidisciplinary team in a specialized center after meticulous planning even though its gigantic tumor size. Local radiotherapy following surgery may improve the rate of recurrence. Besides, closely follow-up and routine examinations are required.
- 7 July 2017
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 18 (9) , 660-665
Open AccessClinicopathological characteristics and experience in the treatment of giant retroperitoneal liposarcoma: A case report and review of the literature
Retroperitoneal liposarcoma (RPLS) is a rare tumor, especailly those over 20 kg that are called “giant liposarcoma," whose characteristics and treatments remain relatively unknown. Herein, we report a giant RPLS measuring 65 × 45 × 30 cm in diameter and 31 kg in weight, which we successfully performed complete excision through interdisciplinary cooperation. The patient had an uneventful postoperative course and was discharged without complications. Afterwards he underwent radiotherapy and had no evidence of tumor recurrence or symptoms of metastasis at 3-month CT scan and 8-month follow-up. We also first review the 13 cases reported in literature published in PubMed regarding giant RPLS. Giant RPLS commonly occurs in adults aged 40–60 y and presents atypical clinical manifestations. CT scan is the most useful examination and preoperative biopsy is controversial. Complete surgical resection still remains the principal treatment. Giant RPLS can also be removed, even reach to R0 excision, by a multidisciplinary team in a specialized center after meticulous planning even though its gigantic tumor size. Local radiotherapy following surgery may improve the rate of recurrence. Besides, closely follow-up and routine examinations are required.
- Open Access
- 18 July 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (7) , e102197
Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG2. Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.
- 18 July 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (7) , e102197
Open AccessPreparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG2. Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy.